Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to $18000.0.

  • Cardiff Oncology's Capital Expenditures changed N/A to $18000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $44000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $80000.0 for FY2024, which is 8625.43% down from last year.
  • As of Q3 2025, Cardiff Oncology's Capital Expenditures stood at $18000.0.
  • In the past 5 years, Cardiff Oncology's Capital Expenditures ranged from a high of $902000.0 in Q1 2025 and a low of -$876000.0 during Q2 2025
  • Its 5-year average for Capital Expenditures is $127800.0, with a median of $107000.0 in 2021.
  • Per our database at Business Quant, Cardiff Oncology's Capital Expenditures surged by 105555.56% in 2022 and then crashed by 8933.33% in 2023.
  • Cardiff Oncology's Capital Expenditures (Quarter) stood at $107000.0 in 2021, then decreased by 29.91% to $75000.0 in 2022, then tumbled by 89.33% to $8000.0 in 2023, then skyrocketed by 900.0% to $80000.0 in 2024, then crashed by 77.5% to $18000.0 in 2025.
  • Its Capital Expenditures stands at $18000.0 for Q3 2025, versus -$876000.0 for Q2 2025 and $902000.0 for Q1 2025.